When to consider liver transplant during the management of chronic liver disease

Medical Clinics of North America

Volumn 98, Issue 1, 2014, Pages 153-168

  Fox, Rena K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic liver disease; Cirrhosis; Clinical practice; Evaluation; Liver transplantation; Primary care; Referral; Timing

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ASCITES; BILE DUCT CARCINOMA; CHILD TURCOTTE PUGH SCORE; CHRONIC LIVER DISEASE; CLINICAL DECISION MAKING; DEATH; DECOMPENSATED LIVER CIRRHOSIS; END STAGE LIVER DISEASE; GASTROINTESTINAL HEMORRHAGE; HEALTH DISPARITY; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT; LIVER TRANSPLANTATION; LONG TERM CARE; LUNG DISEASE; MALNUTRITION; MEDICAL HISTORY; MORTALITY; MOTIVATION; OBESITY; PATIENT REFERRAL; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEPSIS; SOCIAL SUPPORT; SUBSTANCE ABUSE; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

CHRONIC LIVER DISEASE; CIRRHOSIS; CLINICAL PRACTICE; EVALUATION; LIVER TRANSPLANTATION; PRIMARY CARE; REFERRAL; TIMING;

DISEASE MANAGEMENT; DISEASE PROGRESSION; END STAGE LIVER DISEASE; HUMANS; LIVER; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84888038943     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.09.007     Document Type: Review

References (61)

1. Rein D.B., Wittenborn J.S., Weinbaum C.M., et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011, 43(1):66-72.
2. David G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138(2):513-521.
3. Curry M.P. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004, 78(7):955-963.
4. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
5. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
6. Levene A.P., Goldin R.D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012, 61:141-152.
7. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
8. Watt K.D., Charlton M.R. Metabolic syndrome and liver transplantation; a review and guide to management. JHepatol 2010, 53:199-206.
9. Afzali A., Berry K., Ioannou G.N. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012, 18(1):29-37.
10. Barritt A.S., Telloni S.A., Potter C.W., et al. Local access to subspecialty care influences the chance of receiving a liver transplant. Liver Transpl 2013, 19:377-382.
11. US Center for Disease Control and Prevention Vital statistics of the United States 1988, National Center for Health Statistics, Hyattsville (MD), Mortality, 1988-2006.
12. Udell J.A., Wang C.S., Tinmouth J., et al. Does this patient with liver disease have cirrhosis?. JAMA 2012, 307(8):832-842.
13. Mitchell A.E., Colvin H.M., Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010, 51(3):729-733.
14. D'Amico G., Morabito A., Pagliaro L., et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986, 31:468-475.
15. Schepis F., Cammà C., Niceforo D., et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?. Hepatology 2001, 33(2):333-338.
16. Garcia-Tsao G., Friedman S., Iredale J., et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010, 51(4):1445-1449.
17. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. JHepatol 2006, 44:217-231.
18. Grattagliano I., Ubaldi E., Bonfrate L., et al. Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 2011, 17(18):2273-2282.
19. Garcia-Tsao G., Lim J.K., Members of Veterans Affairs Hepatitis C Resource Center Program Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009, 104:1802-1829.
20. Evans R.W. Liver transplants and the decline in deaths from liver disease. Am J Public Health 1997, 87:868-869.
21. Availalble at. Accessed October 15, 2013. http://optn.transplant.hrsa.gov/latestData/rptStrat.asp.
22. Moylan C.A., Brady C.W., Johnson J.L., et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008, 300(20):2371-2378.
23. Mathur A.K., Schaubel D.E., Gong Q., et al. Racial and ethnic disparities in access to liver transplantation. Liver Transpl 2010, 16(9):1033-1040.
24. Bryce C.L., Angus D.C., Arnold R.M., et al. Sociodemographic differences in early access to liver transplantation services. Am J Transplant 2009, 9(9):2092-2101.
25. Lai J.C., Terrault N.A., Vittinghoff E., et al. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transplant 2010, 10(12):2658-2664.
26. Myers R.P., Shaheen A.A., Aspinall A.I., et al. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. JHepatol 2011, 54(3):462-470.
27. Julapalli V.R., Kramer J.R., El-Serag H.B. Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. Liver Transpl 2005, 11:1370-1378.
28. Donovan C.L., Marcovitz P.A., Punch J.D., et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996, 61:1180-1188.
29. Williams K., Lewis J.F., Davis G., et al. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation 2000, 69:2354-2356.
30. Alqahtani S. Update in liver transplantation. Curr Opin Gastroenterol 2012, 28:230-238.
31. Lim J.K., Keeffe E.B. Liver transplantation for alcoholic liver disease: current concepts and length of sobriety. Liver Transpl 2004, 10(10 Suppl 2):S31-S38.
32. Keswani R.N., Ahmed A., Keeffe E.B. Older age and liver transplantation: a review. Liver Transpl 2004, 10(8):957-967.
33. Lipshutz G.S., Busuttil R.W. Liver transplantation in those of advancing age: the case for transplantation. Liver Transpl 2007, 13(10):1355-1357.
34. Nair S., Verma S., Thuluvath P.J. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002, 35(1):105-109.
35. Ahmed A., Keeffe E.B. Current indications and contraindications for liver transplantation. Clin Liver Dis 2007, 11:227-247.
36. Murray K.F., Carithers R.L. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005, 41(6):1407-1432.
37. Malinchoc M., Kamath P.S., Gordon F.D., et al. Amodel to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000, 31:864-871.
38. Kanath P. Amodel to predict survival in patients with end stage liver disease. Hepatology 2001, 33:464-470.
39. Wiesner R., The United Network for Organ Sharing Liver Disease Severity Score Committee Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124:91.
40. Bernardi M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. JHepatol 2011, 54:1297-1306.
41. Freeman R.B., Wiesner R.H., Edwards E., et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004, 10:7-15.
42. Kim W.R., Biggins S.W. Hyponatremia and mortality among patients on the liver-transplant waiting list. NEngl J Med 2008, 359:1018-1026.
43. Freeman R.B., Gish R.G., Harper A., et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006, 12(12 Suppl 3):S128-S136.
44. Merion R.M., Schaubel D.E., Dykstra D.M., et al. The survival benefit of liver transplantation. Am J Transplant 2005, 5:307-313.
45. Martin A.P., Bartels M., Hauss J., et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc 2007, 39(10):3169-3174.
46. Hanto D.W., Fishbein T.M., Pinson C.W., et al. Liver and intestine transplantation: summary analysis 1994-2003. Am J Transplant 2005, 5:916-933.
47. Siciliano M. Liver transplantation in adults: choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012, 3(4):49-61.
48. Starr S.P., Raines D. Cirrhosis: diagnosis, management, and prevention. Am Fam Physician 2011, 84(12):1353-1359.
49. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding varices. Br J Surg 1973, 60:646-649.
50. Boin I.F., Leonardi M.I., Pinto R.S., et al. Liver transplant recipients mortality on the waiting list: long-term comparison to child-pugh classification and MELD. Transplant Proc 2004, 36(4):920-922.
51. Durand F., Valla D. Assessment of the prognosis of cirrhosis: child-Pugh versus MELD. JHepatol 2005, 42:S100-S107.
52. Asrani S.K., Kim W.R. Model for end stage liver disease: end of the first decade. Clin Liver DIs 2011, 15(4):685-698.
53. Cuomo O., Perrella A., Arenga G. Model for end-stage liver disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the child-turcotte-pugh (CTP) system?. Transplantation Proc 2008, 40:1906-1909.
54. Cooper G.S., Bellamy P., Dawson N.V., et al. A prognostic model for patients with end stage liver disease. Gastroenterology 1997, 113:1278-1288.
55. Lucey M.R., Brown K.A., Everson G.T., et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997, 3(6):628-637.
56. Ginés P., Quintero E., Arroyo V., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987, 7:122-128.
57. Arsani S.K., Kamath P.S. Natural history of cirrhosis. Curr Gastroenterol Rep 2013, 15(2):308.
58. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
59. Bruix J., Sherman M., American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
60. Ali J.M., Bonomo L., Brais R., et al. Outcomes and diagnostic challenges posed by incidental cholangiocarcinoma after liver transplantation. Transplantation 2011, 91(12):1392-1397.
61. Shetty K., Rybicki L., Carey W.D. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 1997, 25(5):1049-1053.